1. A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. (26th July 2019) Authors: Hu, Zishuo Ian; Bendell, Johanna C.; Bullock, Andrea; LoConte, Noelle K.; Hatoum, Hassan; Ritch, Paul; Hool, Hugo; Leach, Joseph W.; Sanchez, James; Sohal, Davendra P. S.; Strickler, John; Patel, Ravindranath; Wang‐Gillam, Andrea; Firdaus, Irfan; Yu, Kenneth H.; Kapoun, Ann M.; Holmgren, Eric; Zh... Journal: Cancer medicine Issue: Volume 8:Number 11(2019:Sep.) Page Start: 5148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors. (9th November 2020) Authors: Mahalingam, Devalingam; Harb, Wael; Patnaik, Amita; Ulahannan, Susanna; Mahdi, Haider; Ahluwalia, Manmeet; Patel, Manish; Dowlati, Afshin; Bullock, Andrea; Wen, Patrick; Pant, Shubham; Mulcahy, Mary; Guttendorf, Robert; Vaickus, Lou; Wang, Suming; Crochiere, Marsha; Vincent, Melanie; Cieslewicz, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A399 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy. (9th November 2020) Authors: O'Day, Steven; khoueiry, Anthony El; Ramamurthy, Chethan; Bullock, Andrea; Shapiro, Irina; Han, Haiyong; Namagerdi, Lernik Ohanjanian; Kaleta, Remigiusz; Wijatyk, Anna; Wijatyk, Olivia; Ortuzar, Waldo; Ancukiewicz, Marek; Buell, Jennifer; Chand, Dhan; Gordon, Michael Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors. (10th December 2020) Authors: Mahalingam, Devalingam; Harb, Wael; Patnaik, Amita; Ulahannan, Susanna; Mahdi, Haider; Ahluwalia, Manmeet; Patel, Manish; Dowlati, Afshin; Bullock, Andrea; Wen, Patrick; Pant, Shubham; Mulcahy, Mary; Guttendorf, Robert; Vaickus, Lou; Wang, Suming; Crochiere, Marsha; Vincent, Melanie; Cieslewicz, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CTIM-06. CLINICAL EFFICACY AND BIOMARKER ASSESSMENT OF VT1021, A CD36/CD47 DUAL-TARGETING AGENT, IN RECURRENT GLIOBLASTOMA. (12th November 2021) Authors: Ahluwalia, Manmeet; Battiste, James; Bockorny, Bruno; Bullock, Andrea; Patel, Manish; Wen, Patrick; Shepard, Dale; Vaickus, Lou; Vincent, Melanie; Chen, Jian jenny; Wang, Suming; Watnick, Randolph; Crochiere, Marsha; Cieslewicz, Michael; Watnick, Jing Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. (6th March 2018) Authors: Tolcher, Anthony; Flaherty, Keith; Shapiro, Geoffrey I.; Berlin, Jordan; Witzig, Thomas; Habermann, Thomas; Bullock, Andrea; Rock, Edwin; Elekes, Agnes; Lin, Chester; Kostic, Dusan; Ohi, Naoto; Rasco, Drew; Papadopoulos, Kyriakos P.; Patnaik, Amita; Smith, Lon; Cote, Gregory M. Journal: Oncologist Issue: Volume 23:Number 6(2018) Page Start: 658 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Spontaneous regression of pancreatic cancer with liver metastases. Issue 5 (31st May 2019) Authors: Saade Lemus, Patricia; Anderson, Kevin; Smith, Martin; Bullock, Andrea Journal: BMJ case reports Issue: Volume 12:Issue 5(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study). (13th December 2012) Authors: Zwicker, Jeffrey I.; Liebman, Howard A.; Bauer, Kenneth A.; Caughey, Thomas; Campigotto, Federico; Rosovsky, Rachel; Mantha, Simon; Kessler, Craig M.; Eneman, Jonathan; Raghavan, Vidya; Lenz, Heinz‐Joseph; Bullock, Andrea; Buchbinder, Elizabeth; Neuberg, Donna; Furie, Bruce Journal: British journal of haematology Issue: Volume 160:Number 4(2013:Feb.) Page Start: 530 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Response in BRCA1 mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX. Issue 4 (29th April 2022) Authors: Campoverde, Leticia Estefania; Batalini, Felipe; Bulushi, Yarab; Bullock, Andrea Journal: BMJ case reports Issue: Volume 15:Issue 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗